Viyash Scientific Ltd (VIYASH) is currently trading at 202.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Viyash Scientific Limited, formerly Sequent Scientific Limited, is engaged in the pharmaceutical business with a focus on animal health, formulations, and API. The company has shown solid financial performance in Q3 FY26, with revenues of ₹8,584 million and EBITDA growing by 64% YoY. It has achieved significant margin expansion, reflecting strong operational efficiencies and strategic cost optimization. The merger with Sequent Scientific Limited has enabled Viyash to unlock synergies across various business units, enhancing R&D, manufacturing capabilities, and market reach. This transformative merger has laid a strong foundation for sustained profitability and business growth. Viyash has successfully entered into strategic partnerships, including a noteworthy agreement with Boehringer Ingelheim for distributing companion animal products in India, underscoring its commitment to expanding its footprint in the animal health sector. The company is focusing on expanding its R&D capabilities, emphasizing the development of complex generics, which positions it to capture significant opportunities in the growing generics market for companion animals.

Over the past 52 weeks, Viyash Scientific Ltd has traded between a low of ₹111.00 and a high of ₹260.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Viyash Scientific Ltd has a market capitalization of approximately 8,791.39. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Viyash Scientific Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 116.47 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 8,791.39 Cr, Viyash Scientific Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Viyash Scientific Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Viyash Scientific Ltd is 116.47. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The loan-linked subsidy scheme for the private veterinary sector and the ₹10,000 crore 'Biopharma Shakti' initiative are the two most significant announcements, as they directly expand the company's market and strengthen the entire pharmaceutical ecosystem.